Aptamers are a class of therapeutic oligonucleotides that form specific three-dimensional structures that are dictated by their sequences. They are typically generated by an iterative screening process of complex nucleic acid libraries employing a process termed Systemic Evolution of Ligands by Exponential Enrichment (SELEX). SELEX has traditionally been performed using purified proteins, and cell surface receptors may be challenging to purify in their properly folded and modified conformations. Therefore, relatively few aptamers have been generated that bind cell surface receptors. However, improvements in recombinant fusion protein technology have increased the availability of receptor extracellular domains as purified protein targets, and the development of cell-based selection techniques has allowed selection against surface proteins in their native configuration on the cell surface. With cell-based selection, a specific protein target is not always chosen, but selection is performed against a target cell type with the goal of letting the aptamer choose the target. Several studies have demonstrated that aptamers that bind cell surface receptors may have functions other than just blocking receptor-ligand interactions. All cell surface proteins cycle intracellularly to some extent, and many surface receptors are actively internalized in response to ligand binding. Therefore, aptamers that bind cell surface receptors have been exploited for the delivery of a variety of cargoes into cells. This review focuses on recent progress and current challenges in the field of aptamer-mediated delivery.
References
[1]
Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature？1990, 346, 818–822, doi:10.1038/346818a0. 1697402
[2]
Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science？1990, 249, 505–510.
[3]
Knudsen, S.M.; Robertson, M.P.; Ellington, A.D. In vitro selection using modified or unnatural nucleotides. Curr. Protoc. Nucleic Acid Chem.？2002, Chapter 9. Unit 9.6.
[4]
Sledz, C.A.; Holko, M.; de Veer, M.J.; Silverman, R.H.; Williams, B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol.？2003, 5, 834–839.
[5]
Okahira, S.; Nishikawa, F.; Nishikawa, S.; Akazawa, T.; Seya, T.; Matsumoto, M. Interferon-beta induction through toll-like receptor 3 depends on double-stranded RNA structure. DNA Cell Biol.？2005, 24, 614–623.
[6]
Healy, J.M.; Lewis, S.D.; Kurz, M.; Boomer, R.M.; Thompson, K.M.; Wilson, C.; McCauley, T.G. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res.？2004, 21, 2234–2246.
[7]
Bunka, D.H.; Stockley, P.G. Aptamers come of age—At last. Nat. Rev. Microbiol.？2006, 4, 588–596.
[8]
Gold, L. Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem.？1995, 270, 13581–13584. 7775406
[9]
White, R.R.; Sullenger, B.A.; Rusconi, C.P. Developing aptamers into therapeutics. J. Clin. Invest.？2000, 106, 929–934.
[10]
Nimjee, S.M.; Rusconi, C.P.; Sullenger, B.A. Aptamers: An emerging class of therapeutics. Annu. Rev. Med.？2005, 56, 555–583.
Khati, M.; Schuman, M.; Ibrahim, J.; Sattentau, Q.; Gordon, S.; James, W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J. Virol.？2003, 77, 12692–12698.
[13]
Chen, C.H.; Dellamaggiore, K.R.; Ouellette, C.P.; Sedano, C.D.; Lizadjohry, M.; Chernis, G.A.; Gonzales, M.; Baltasar, F.E.; Fan, A.L.; Myerowitz, R.; Neufeld, E.F. Aptamer-based endocytosis of a lysosomal enzyme. Proc. Natl. Acad. Sci. USA？2008, 105, 15908–15913.
[14]
Lupold, S.E.; Hicke, B.J.; Lin, Y.; Coffey, D.S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res.？2002, 62, 4029–4033.
[15]
Santulli-Marotto, S.; Nair, S.K.; Rusconi, C.; Sullenger, B.; Gilboa, E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res.？2003, 63, 7483–7489.
[16]
Cerchia, L.; Duconge, F.; Pestourie, C.; Boulay, J.; Aissouni, Y.; Gombert, K.; Tavitian, B.; de Franciscis, V.; Libri, D. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol.？2005, 3, e123.
[17]
Mi, J.; Zhang, X.; Giangrande, P.H.; McNamara, J.O., 2nd; Nimjee, S.M.; Sarraf-Yazdi, S.; Sullenger, B.A.; Clary, B.M. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem .Biophys. Res. Commun.？2005, 338, 956–963, doi:10.1016/j.bbrc.2005.10.043. 16256939
[18]
Ohuchi, S.P.; Ohtsu, T.; Nakamura, Y. Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. Biochimie？2006, 88, 897–904.
[19]
McNamara, J.O.; Kolonias, D.; Pastor, F.; Mittler, R.S.; Chen, L.; Giangrande, P.H.; Sullenger, B.; Gilboa, E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest.？2008, 118, 376–386.
[20]
Dollins, C.M.; Nair, S.; Boczkowski, D.; Lee, J.; Layzer, J.M.; Gilboa, E.; Sullenger, B.A. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem. Biol.？2008, 15, 675–682.
[21]
Mi, J.; Liu, Y.; Rabbani, Z.N.; Yang, Z.; Urban, J.H.; Sullenger, B.A.; Clary, B.M. In vivo selection of tumor-targeting RNA motifs. Nat. Chem. Biol.？2010, 6, 22–24. 19946274
[22]
Li, N.; Larson, T.; Nguyen, H.H.; Sokolov, K.V.; Ellington, A.D. Directed evolution of gold nanoparticle delivery to cells. Chem. Commun.？, 46, 392–394.
[23]
Thiel, K.W.; Giangrande, P.H. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides？2009, 19, 209–222.
[24]
Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanotechnology and aptamers: Applications in drug delivery. Trends Biotechnol.？2008, 26, 442–449.
Shieh, Y.A.; Yang, S.J.; Wei, M.F.; Shieh, M.J. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano？2010, 4(3), 1433–1442. 20166743
[27]
Hwang do, W.; Ko, H.Y.; Lee, J.H.; Kang, H.; Ryu, S.H.; Song, I.C.; Lee, D.S.; Kim, S. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J. Nucl. Med.？2009, 51, 98–105.
Wullner, U.; Neef, I.; Eller, A.; Kleines, M.; Tur, M.K.; Barth, S. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Targets？2008, 8, 554–565.
[31]
Chu, T.C.; Marks, J.W., III; Lavery, L.A.; Faulkner, S.; Rosenblum, M.G.; Ellington, A.D.; Levy, M. Aptamer: Toxin conjugates that specifically target prostate tumor cells. Cancer Res.？2006, 66, 5989–5992. 16778167
[32]
Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P.W.; Langer, R.; Farokhzad, O.C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett.？2007, 7, 3065–3070, doi:10.1021/nl071546n. 17854227
[33]
Farokhzad, O.C.; Cheng, J.; Teply, B.A.; Sherifi, I.; Jon, S.; Kantoff, P.W.; Richie, J.P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA？2006, 103, 6315–6320.
[34]
Dhar, S.; Gu, F.X.; Langer, R.; Farokhzad, O.C.; Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA？2008, 105, 17356–17361.
[35]
Zhou, J.; Li, H.; Li, S.; Zaia, J.; Rossi, J.J. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther.？2008, 16, 1481–1489.
[36]
Ferreira, C.S.; Cheung, M.C.; Missailidis, S.; Bisland, S.; Gariepy, J. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res.？2009, 37, 866–876.
[37]
Pieve, C.D.; Perkins, A.C.; Missailidis, S. Anti-MUC1 aptamers: radiolabelling with (99 m)Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl. Med. Biol.？2009, 36, 703–710.
[38]
Huang, Y.F.; Shangguan, D.; Liu, H.; Phillips, J.A.; Zhang, X.; Chen, Y.; Tan, W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem？2009, 10, 862–868.
[39]
Wu, Y.; Sefah, K.; Liu, H.; Wang, R.; Tan, W. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc. Natl. Acad. Sci. USA？2010, 107, 5–10.
[40]
Jahkola, T.; Toivonen, T.; Nordling, S.; von Smitten, K.; Virtanen, I. Expression of tenascin-C in intraductal carcinoma of human breast: Relationship to invasion. Eur. J. Cancer？1998, 34, 1687–1692.
[41]
Erickson, H.P.; Bourdon, M.A. Tenascin: An extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu. Rev. Cell Biol.？1989, 5, 71–92.
[42]
Daniels, D.A.; Chen, H.; Hicke, B.J.; Swiderek, K.M.; Gold, L. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment. Proc. Natl. Acad. Sci. USA？2003, 100, 15416–15421.
[43]
Hicke, B.J.; Marion, C.; Chang, Y.F.; Gould, T.; Lynott, C.K.; Parma, D.; Schmidt, P.G.; Warren, S. Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem.？2001, 276, 48644–48654.
[44]
Tasch, J.; Gong, M.; Sadelain, M.; Heston, W.D. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy? Crit. Rev. Immunol.？2001, 21, 249–261.
[45]
Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N.H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res.？1997, 57, 3629–3634.
Kim, E.; Jung, Y.; Choi, H.; Yang, J.; Suh, J.S.; Huh, Y.M.; Kim, K.; Haam, S. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials？2010, 31, 4592–4599.
[48]
Barre-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science？1983, 220, 868–871.
[49]
Gallo, R.C.; Sarin, P.S.; Gelmann, E.P.; Robert-Guroff, M.; Richardson, E.; Kalyanaraman, V.S.; Mann, D.; Sidhu, G.D.; Stahl, R.E.; Zolla-Pazner, S.; Leibowitch, J.; Popovic, M. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science？1983, 220, 865–867.
[50]
Dalgleish, A.G.; Beverley, P.C.; Clapham, P.R.; Crawford, D.H.; Greaves, M.F.; Weiss, R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature？1984, 312, 763–767.
[51]
Berger, E.A.; Doms, R.W.; Fenyo, E.M.; Korber, B.T.; Littman, D.R.; Moore, J.P.; Sattentau, Q.J.; Schuitemaker, H.; Sodroski, J.; Weiss, R.A. A new classification for HIV-1. Nature？1998, 391, 240.
[52]
Melikyan, G.B.; Markosyan, R.M.; Hemmati, H.; Delmedico, M.K.; Lambert, D.M.; Cohen, F.S. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol.？2000, 151, 413–423.
[53]
Dey, A.K.; Khati, M.; Tang, M.; Wyatt, R.; Lea, S.M.; James, W. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J. Virol.？2005, 79, 13806–13810.
[54]
Dey, A.K.; Griffiths, C.; Lea, S.M.; James, W. Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA？2005, 11, 873–884.
[55]
Zhou, J.; Swiderski, P.; Li, H.; Zhang, J.; Neff, C.P.; Akkina, R.; Rossi, J.J. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res.？2009, 37, 3094–3109.
[56]
Orrick, L.R.; Olson, M.O.; Busch, H. Comparison of nucleolar proteins of normal rat liver and Novikoff hepatoma ascites cells by two-dimensional polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. USA？1973, 70, 1316–1320.
[57]
Ginisty, H.; Sicard, H.; Roger, B.; Bouvet, P. Structure and functions of nucleolin. J. Cell. Sci.？1999, 112, 761–772. (Pt 6).
[58]
Westmark, C.J.; Malter, J.S. Up-regulation of nucleolin mRNA and protein in peripheral blood mononuclear cells by extracellular-regulated kinase. J. Biol. Chem.？2001, 276, 1119–1126.
[59]
Christian, S.; Pilch, J.; Akerman, M.E.; Porkka, K.; Laakkonen, P.; Ruoslahti, E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol.？2003, 163, 871–878.
[60]
Kadomatsu, K.; Muramatsu, T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett.？2004, 204, 127–143.
[61]
Bates, P.J.; Laber, D.A.; Miller, D.M.; Thomas, S.D.; Trent, J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol.？2009, 86, 151–164.
[62]
Soundararajan, S.; Chen, W.; Spicer, E.K.; Courtenay-Luck, N.; Fernandes, D.J. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res.？2008, 68, 2358–2365.
[63]
Ireson, C.R.; Kelland, L.R. Discovery and development of anticancer aptamers. Mol. Cancer Ther.？2006, 5, 2957–2962.
[64]
Drecoll, E.; Gaertner, F.C.; Miederer, M.; Blechert, B.; Vallon, M.; Muller, J.M.; Alke, A.; Seidl, C.; Bruchertseifer, F.; Morgenstern, A.; Senekowitsch-Schmidtke, R.; Essler, M. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One？2009, 4, e5715.
[65]
Klausner, R.D.; Van Renswoude, J.; Ashwell, G.; Kempf, C.; Schechter, A.N.; Dean, A.; Bridges, K.R. Receptor-mediated endocytosis of transferrin in K562 cells. J. Biol. Chem.？1983, 258, 4715–4724.
[66]
Dautry-Varsat, A.; Ciechanover, A.; Lodish, H.F. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. USA？1983, 80, 2258–2262.
[67]
Lepelletier, Y.; Camara-Clayette, V.; Jin, H.; Hermant, A.; Coulon, S.; Dussiot, M.; Arcos-Fajardo, M.; Baude, C.; Canionni, D.; Delarue, R.; Brousse, N.; Benaroch, P.; Benhamou, M.; Ribrag, V.; Monteiro, R.C.; Moura, I.C.; Hermine, O. Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res.？2007, 67, 1145–1154.
[68]
Gendler, S.J. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia？2001, 6, 339–353.
[69]
Altschuler, Y.; Kinlough, C.L.; Poland, P.A.; Bruns, J.B.; Apodaca, G.; Weisz, O.A.; Hughey, R.P. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol. Biol. Cell？2000, 11, 819–831.
[70]
Muller-Tidow, C.; Schwable, J.; Steffen, B.; Tidow, N.; Brandt, B.; Becker, K.; Schulze-Bahr, E.; Halfter, H.; Vogt, U.; Metzger, R.; Schneider, P.M.; Buchner, T.; Brandts, C.; Berdel, W.E.; Serve, H. High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin. Cancer Res.？2004, 10, 1241–1249.
[71]
Shangguan, D.; Li, Y.; Tang, Z.; Cao, Z.C.; Chen, H.W.; Mallikaratchy, P.; Sefah, K.; Yang, C.J.; Tan, W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA？2006, 103, 11838–11843.
[72]
Shangguan, D.; Cao, Z.; Meng, L.; Mallikaratchy, P.; Sefah, K.; Wang, H.; Li, Y.; Tan, W. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res.？2008, 7, 2133–2139.
[73]
Tong, G.J.; Hsiao, S.C.; Carrico, Z.M.; Francis, M.B. Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J. Am. Chem. Soc.？2009, 131, 11174–11178.
[74]
Xiao, Z.; Shangguan, D.; Cao, Z.; Fang, X.; Tan, W. Cell-specific internalization study of an aptamer from whole cell selection. Chemistry？2008, 14, 1769–1775.
[75]
Kang, H.; O'Donoghue, M.B.; Liu, H.; Tan, W. A liposome-based nanostructure for aptamer directed delivery. Chem. Commun.？2010, 46, 249–251.
[76]
Taghdisi, S.M.; Abnous, K.; Mosaffa, F.; Behravan, J. Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer. J. Drug Target？2010, 18, 277–281.
[77]
Cambier, J.C.; Campbell, K.S. Membrane immunoglobulin and its accomplices: new lessons from an old receptor. FASEB J.？1992, 6, 3207–3217.
[78]
Thomas, M.D.; Srivastava, B.; Allman, D. Regulation of peripheral B cell maturation. Cell Immunol.？2006, 239, 92–102.
[79]
Mallikaratchy, P.; Tang, Z.; Kwame, S.; Meng, L.; Shangguan, D.; Tan, W. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol. Cell Proteomics？2007, 6, 2230–2238.
[80]
Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell？1990, 61, 203–212.
